Literature DB >> 10706022

Ocular motor abnormalities in Gaucher disease.

C M Harris1, D S Taylor, A Vellodi.   

Abstract

Gaucher disease (GD) without primary neurological involvement (GD1) is now treatable with exogenous enzyme replacement therapy (ERT). ERT does not halt the fatal neurological progression of type 2 (infantile) disease (GD2), but in type 3 disease (GD3), neurological progression may be slowed down or possibly halted in some cases by higher doses of ERT. Therefore, it is crucial to distinguish between GD1 and GD3 disease for appropriate treatment. Saccade initiation failure (SIF) (ocular motor apraxia, supranuclear gaze palsy) is often the earliest neurological sign in GD3. This sign can be difficult to detect clinically, but is readily revealed as missed quick-phases during induced optokinetic and vestibular nystagmus. We investigated whether objective ocular motor assessment could improve the detection of GD3 disease. Eight children, diagnosed enzymatically with GD, were tested using D.C.-electro-oculography and/or video. In 6 children, optokinetic and vestibular nystagmus showed marked paucity of quick-phases making the eyes "lock up" at the limit of gaze, thus indicating SIF. In 3 cases the diagnosis was revised from GD1 to GD3. The diagnosis of GD3 was made in two children who were too ill for clinical assessment of SIF. Only 1 child had previous clinical evidence of SIF, and so GD3 was confirmed. One child was normal and the diagnosis of another remains uncertain. These results show that the possibility of SIF and hence GD3 may not be excluded by clinical examination alone. Thus we recommend that, where possible, objective eye movement assessment be carried out in children with GD.

Entities:  

Mesh:

Year:  1999        PMID: 10706022     DOI: 10.1055/s-2007-973507

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  20 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

Review 2.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 3.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

4.  Comparison of the main sequence of reflexive saccades and the quick phases of optokinetic nystagmus.

Authors:  S Garbutt; M R Harwood; C M Harris
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

Review 5.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 6.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

7.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

8.  Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Samuel L Kelly; Jessica R Bame; Jingjing Duan; Vera Shinder; Alfred H Merrill; Kostantin Dobrenis; Anthony H Futerman
Journal:  Hum Mol Genet       Date:  2013-09-24       Impact factor: 6.150

9.  A model of neuronopathic Gaucher disease.

Authors:  P E Campbell; C M Harris; C M Harris; T Sirimanna; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Vestibular and Saccadic Abnormalities in Gaucher's Disease.

Authors:  Luke Chen; G Michael Halmagyi; Michael J Todd; Swee T Aw
Journal:  JIMD Rep       Date:  2013-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.